x
Corporate Summary

Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.

 

Presentations

 

Press Releases
  • Dec 01 ,2021

    BETHESDA, Md., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman and Chief Scientific Officer Xavier Barril, Ph.D. of Gain Therapeutics, will present a corporate overview at the Imagine AI + Healthcare Investor Summit being...

    Read More >

  • Nov 12 ,2021

    Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF’s Parkinson's Disease Therapeutics Conference--- Appoints Matthias Alder as Chief Operating Officer and Appoints 5 Members to Newly Formed Scientific Advisory Board---$40.98 Million in Cash as of September 30, 2021, Provides Runway into Second half of 2023 and a Strong Cash Position to Transition the Company’s Lead Program into Clinical Trials...

    Read More >

  • Nov 11 ,2021

    Brain-penetrant structurally targeted allosteric regulators for glucocerebrosidase (GCase) show promising in vivo pharmacological activity in Parkinson’s Disease animal model BETHESDA, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today presented preclinical data during a...

    Read More >

 

MORE



Stock Information
GANX



Contact IR

Company

GAIN THERAPEUTICS INC.

4800 Hampden Ln, St 200
Bethesda, MD 20814,
United State

Phone: +1 301 500 1556

Investor Relations

LifeSci Advisors, LLC

Dan Ferry
1 International Place
14th Floor
Boston, MA 02110

Phone: +1 617-430-7576
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Alerts Sign Up

Form by ChronoForms - ChronoEngine.com